PPMI Completed & Ongoing Biologic Analyses

	Principal Investigator	Organization	Project Title	Data Availability	Analyte	Matrix	Included Enrollment Cohorts	Subcategories included	Visit(s)	Project ID	Notes
	Collaboration powered by Smartsheet   |   Report Abuse
1	Andrew Singleton, PhD	NIA	APOE4 Genotyping​	Currently available	APOE4 genotyping​	DNA from whole blood	Healthy Control Parkinson Disease SWEDD (legacy)	N/A	Baseline	104
2	Clemens Scherzer, MD	Harvard	Evaluation of PD-linked Transcripts in PPMI	Currently available	aSyn transcripts	RNA from whole blood	Healthy Control Parkinson Disease	N/A	Baseline	105
3	Andrew Singleton, PhD	NIA	Selected Genetic Variants Genotyped Using NeuroX Array	Currently available	NeuroX genotyping	DNA from whole blood	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baseline	106, 107
4	Andrew Singleton, PhD	NIA	Immunochip Genotyping on DNA Samples from PPMI	Currently available	Immunochip genotyping​	DNA from whole blood	Healthy Control Parkinson Disease SWEDD (legacy)	N/A	Baseline	108
5	Les Shaw, PhD	UPenn	A-beta 1-42, t-tau and p-tau 181 Measurements in PPMI CSF Samples using xMAP/Luminex Multiplex Immunoassay & Roche Elecsys	Currently available	Aβ, tau, & p-tau181 ​	CSF	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baseline, 6, 12, 24, 36 months	110, 125	Innogentics: PD, HC, & SWEDD through yr 1; Elecsys: PD, HC, & SWEDD through yr 3, prodromal & genetic through yr 1
6	Alice Chen-Plotkin, MD, MSc	UPenn	Plasma Apolipoprotein A1 Level as a Biomarker in Parkinson’s Disease	Currently available	ApoA1 & EGF​	Plasma	Healthy Control Parkinson Disease	N/A	Baseline, 6, 12 months	112
7	Maria Teresa Pellecchia, PhD	University of Salerno	Insulin-like Growth Factor-1 as a Biomarker of Early Cognitive Impairment in PD	Currently available	IGF-1	Serum	Healthy Control Parkinson Disease	N/A	Baseline	113
8	Judith Potashkin, PhD	Rosalind & Franklin University	Whole blood RNA Biomarkers of PD	Currently available	mRNA transcripts	RNA from whole blood	Healthy Control Parkinson Disease	N/A	Baseline	114
9	Matthew Farrer, PhD	University of BC	Clinical, Imaging, & Plasma & CSF Correlates of aSyn Genomic Variability	Currently available	SNCA genotyping​	DNA from whole blood	Healthy Control Parkinson Disease	N/A	Baseline	115
10	Andrew Singleton, PhD	NIA	Exome Sequencing of PPMI samples	Currently available	Whole exome sequencing	DNA from whole blood	Healthy Control Parkinson Disease SWEDD (legacy)	N/A	Baseline	116
11	Andrew Singleton, PhD	NIA	Whole Genome Sequencing & Analysis of PPMI Prodromal & Genetic Cohorts & Genetic Registry​	Currently available	Whole genome sequencing	DNA from whole blood	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baseline	118
12	Martin Rabey, MD	BioShai Ltd.	Validation of a blood-based Gene Expression Assay for Early Diagnosis & Monitoring Disease	Currently available	mRNA transcripts	RNA from whole blood	Healthy Control Parkinson Disease SWEDD (legacy)	N/A	Baseline, 12, 24, 36 months	119
13	Dena Hernandez, PhD	NIA​	DNA Methylation in PPMI	Currently available	Dna methylation	DNA from whole blood	Healthy Control Parkinson Disease SWEDD (legacy)	N/A	Baseline	120
14	Thomas Kremer, PhD; Kristen Taylor, PhD	Roche	CSF Neurotransmitter Metabolites as Promising Diagnostic & Disease Severity Biomarkers in Early-Stage PD Patients​	Currently available	Catecholamines​	CSF	Healthy Control Parkinson Disease	N/A	Baseline, 12, 24 months	122
15	Dwight German, PhD	UT Southwestern	Blood Biomarker for PD	Currently available	PD2 peptoid	Serum	Healthy Control Parkinson Disease	N/A	Baseline	123
16	Peggy Taylor, PhD	BioLegend	aSyn Measurements in Longitudinal CSF Samples From De Novo, PD, CT, SWEDD, Prodromal, & Genetic Cohorts​	Currently available	total aSyn, hemoglobin, & total protein	CSF	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baseline, 6, 12, 24, 36 months	124	PD, HC, SWEDD through yr 3, prodromal & genetic through yr 1
17	Andrew Singleton, PhD	NIA	GBA Sequencing	Currently available	GBA sequencing	DNA from whole blood	Healthy Control Parkinson Disease SWEDD (legacy)	N/A	Baseline	126
18	Satpal Virdee, PhD,	University of Dundee​	Profiling PINK1-Parkin Functionality in Patient Fibroblasts Using Chemical Probes	Currently available	PINK1	Fibroblasts	Healthy Control Parkinson Disease	N/A	N/A	127
19	Xinnan Wang, PhD	Stanford University​	Miro, a Biomarker for Parkinson’s Disease	Currently available	Miro	Fibroblasts iPSCs	Healthy Control Parkinson Disease Prodromal	Genetic subjects	N/A	129
20	Gavin Hudson, PhD	Newcastle University	The Role of Cell-Free Mitochondrial DNA in Neurodegenerative Disease	Currently available	Cell-free mitochondrial Dna	CSF	Healthy Control Parkinson Disease	N/A	Baseline, 36 months	130
21	Kendall Van Keuren-Jensen, PhD	TGen Foundation	RNAseq in PPMI	Currently available (summary files, raw data for cloud transfer, & data explorer)​	mRNA& miRNA sequencing​	RNA from whole blood	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baselilne, 6, 12, 24, 36 months	131, 133	Data available as summary files, raw data for cloud transfer, & data explorer
22	Pablo Sardi, PhD	Sanofi	GBA-Related Biomarkers in Parkinson's Disease	Currently available	GCase activity & sphingolipids​	CSF Plasma Whole blood	Healthy Control Parkinson Disease SWEDD (legacy)	N/A	Baseline, 12, 24, 36 months	132, 135
23	Nilima Prakash, PhD	Hamm-Lippstadt University of Applied Sciences​	Altered Calcium Activity Patterns in Developing Dopaminergic Neurons from PD Patients as an Early Indicator of Disease Predisposition or Progression	Currently available	Calcium activity	Fibroblasts iPSCs	Healthy Control Parkinson Disease	N/A	N/A	136
24	Rachit Bakshi, PhD	MGH/MIND​	Urate & Nrf2 Pathway Effects on Mutant LRRK2 Toxicity in iPSC-Derived DA Neurons	Currently available	Urate & Nrf2​	iPSCs	Healthy Control Parkinson Disease Prodromal	LRRK2 subjects	N/A	137
25	Mark Cookson, PhD​	NIA	LRRK2 Genetic Risk Variants in PD	Expected Q2 2024	LRRK2 functional variants​	iPSCs	Healthy Control Parkinson Disease Prodromal	Genetic subjects	N/A	139
26	Travis Dunckley, PhD; Paula Desplats, PhD	ArizoN/A State University; UCSD	Comprehensive Methylation Profiling of the PPMI Cohort​	Currently available	Methylation profiling​	DNA from whole blood	Healthy Control Parkinson Disease Prodromal	LRRK2 subjects	Baseline, 12, 24, 36 months	140
27	Nic Dzamko, PhD	University of Sydney​	Inflammatory phenotypes in differentiated human LRRK2 & GBA mutation IPS cell lines	Currently available	Inflammation/​lysosomal function	iPSCs	Healthy Control Parkinson Disease Prodromal	GBA & LRRK2 subjects	N/A	141
28	Danielle Graham, PhD; Brit Mollenhauer, MD	Biogen; Paracelsus EleN/A Klinik	Investigation of Neurofilament Light Chain in Serum from the PPMI Cohorts as Progression Marker for PD​	Currently available	Neurofilament Light (NFL)​	Serum	Healthy Control Parkinson Disease Prodromal	Genetic subjects	PD & HC: Baseline, 6, 12, 24, 36, 60 months; Prodromal & genetic cohorts: Baseline, 6, 12, 24, 36 months	144
29	Kalpana Merchant, PhD	TransThera	Do Urinary BMP Levels Change with Disease Progression in Idiopathic & Genetic PD?	Currently available	BMP	Urine	Healthy Control Parkinson Disease Prodromal	GBA & LRRK2 subjects	PD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months	145
30	Dimitri Krainc, MD	Northwestern University	Convergence of LRRK2 & GBA1 in the Pathogenesis of Parkinson’s Disease	Currently available	GCase activity in dopaminergic neurons​	iPSCs	Healthy Control Parkinson Disease	LRRK2 subjects	N/A	148
31	Matt LaVoie, PhD	Brigham & Women’s, Harvard​	Role of LRRK2 in Gcase-mediated Alterations in Lysosome Functions & aSyn Metabolism	Currently available	LRRK2 at lysosomes	iPSCs	Parkinson Disease	GBA subjects	N/A	149
32	Andy Singleton, PhD	NIA	The Foundational Data Initiative	Currently available	Transcriptional activity, gene regulation, epigenetics​	iPSCs	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	N/A	150	Data portal under development
33	Fiona Elwood, PhD	Novartis	Identification of Proteins & Protein Networks in Human CSF That Differentiate Within PD Patients​	Currently available	SomaLogic collaboration (with Merck & Novartis)​	CSF	Healthy Control Parkinson Disease Prodromal	Genetic subjects	Baseline	151
34	Richard Batrla-Utermann, PhD	Roche	Roche NeuroTool Kit	Currently available	Roche Elecsys NeuroTool Kit (aSyn, GFAP, IL-6, S100b, neurogranin, NFL, sTREM2, YKL40)​	CSF	Healthy Control Parkinson Disease	N/A	Baseline, 6, 12, 24, 36, 48 months	152
35	Thomas Schwarz, PhD	Boston Children’s Hospital​	Mitochondrial Transport Defects as a Potential Biomarker in Patient-derived Cells	Currently available	Mitochondrial transport​	iPSCs	Healthy Control Parkinson Disease	Genetic subjects	N/A	153
36	Ellen Sidransky, MD​	NIH	Development of Novel TRPML1 Activator for Treatment of PD	Data unavailable	Calcium channel agonists	iPSCs	Healthy Control Parkinson Disease	N/A	N/A	154
37	Claudio Soto, PhD	Amprion	Monitoring the Progression & Pre-clinical Diagnosis of PD by Detection of aSyn Oligomers in CSF Using the PMCA Assay	Currently available	aSyn seeding (PMCA)- Round Robin & Phase 2​	CSF	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Phase 1: Baseline, 36, mo; Phase 2: PD, HC, SWEDD at Baseline, prodromals at all visits, SNCA at all visits, LRRK2/GBA PD at Baseline and NMC at Baseline & all visits for phenoconverted	155	Phase 1 (bl & 36 months) PD, CT, SWEDD currently available; remaining data expected EOY
38	Aaron Day Williams	Flagship 60​	Investigation of Phenotypic Differences Between Familial PD, Idiopathic PD and Controls in Patient-derived iPSCs	Currently available	Phenotyping	iPSCs	Healthy Control Parkinson Disease Prodromal	LRRK2 subjects	N/A	156
39	Marlene Jacobson, PhD	University of Dundee​	Investigating the Effect of Small Molecules to Rescue Lysosomal & GBA-1 Deficiencies in GBA-PD	Currently available	Lysosomal rescue​	Fibroblasts	Healthy Control Parkinson Disease	N/A	N/A	158
40	Les Shaw, PhD	UPenn	PPMI CSF A-beta42, t-tau, and p-tau 181 Analysis 2019	Currently available	Aβ, tau, & p-tau181 ​	CSF	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baseline, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 months	159	75 Bridging study & 2,000+ remaining PPMI samples not yet aN/Alyzed from previous efforts
41	Sulev Koks, MD, PhD	Murdoch University	Association of Repetitive Elements with Parkinson's Disease Risk and Progression in the PPMI Cohort	Currently available	Tandem repeats	DNA from whole blood	Healthy Control Parkinson Disease	N/A	Baseline	160
42	Maximiliano Gutierrez, PhD	Francis Crick Institute​	The Role of LRRK2 Kinase Activity in Human Macrophage Function	Currently available	LRRK2 kinase activity	iPSCs	Parkinson Disease	LRRK2 subjects	N/A	161
43	Liana Rosenthal, MD	John Hopkins	Is Poly ADP-ribose in the CSF a Biomarker for PD Diagnosis or Progression?​	Currently available	Poly ADP-ribose​	CSF	Healthy Control Parkinson Disease	N/A	Baseline, 6, 12, 18, 24, 36,48, 60 months	165
44	Eleanor Coffey, PhD	Turku Centre for Biotechnology​	PD Signature Validation Project Related to "Improving Patient Diagnosis, Stratification & Disease Monitoring in PD	Expected Q3 2024	Protein handling	PBMCs	Healthy Control Parkinson Disease Prodromal	Genetic subjects	3 longitudinal timepoints	170
45	Cornelis Blauwendraat, PhD	NIA	Long read DNA sequencing of the PPMI cohort​	Expected Q2 2024	Long read Dna sequencing​	DNA from whole blood	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baseline	171
46	Byron Caughey, PhD	NIH	aSyn Seeding Assay Round Robin- NIH​	Currently available	aSyn seeding​ (RT-QuIC)- Round Robin	CSF	Healthy Control Parkinson Disease SWEDD (legacy)	N/A	Baseline, 36 months	172
47	Roland Heym, PhD	Abbvie	Evaluation of Seeding-competent aSyn in the CSF as a Biomarker for Parkinson’s Disease	Currently available	aSyn seeding​ (RT-QuIC)- Round Robin	CSF	Healthy Control Parkinson Disease SWEDD (legacy)	N/A	Baseline, 36 months	173
48	Dong-Gyu Jo, PhD	Sungkyunkwan University​	Study for the Propagation of aSyn (Screening the Propagation Relative Genes)	Expected Q4 2024	aSyn propagation	iPSCs	Healthy Control Parkinson Disease	GBA & LRRK2 subjects	N/A	174
49	Kirsten Taylor, PhD	Roche	aSyn PMCA Assay at Amprion	Currently available	aSyn seeding​ (PMCA in leftover samples)	CSF	Healthy Control Parkinson Disease	N/A	Baseline, 12, 24 months	176
50	Jennifer Van Eyk, PhD	Cedars-Sinai	Post-Translational Modification & Protein Quantification of Plasma & CSF	Currently available	Unbiased proteomics (DIA MS, AMP PD)	CSF Plasma	Healthy Control Parkinson Disease	N/A	Baseline & 3 longitudinal timepoints	177
51	Kimberly Billingsley, PhD	NIH	Identifying the Role of Structural Variants in PD	Expected Q3 2024	Structural variants	DNA from whole blood	Healthy Control Parkinson Disease	N/A	Various	179
52	Michael Schwarzschild, PhD	MGH & Denali	Metabolomic Analysis of Penetrance, Prognosis, & Tracking Biomarkers of LRRK2 PD	Plasma available; CSF Expected Q2 2024	Metabolomics	CSF Plasma	Healthy Control Parkinson Disease Prodromal	GBA & LRRK2 subjects	Plasma: Baseline,12, 24 months; CSF: Baseline only	180, 215
53	Marion Buckwalter, PhD	Stanford	Adaptive Immune Markers for Predicting Cognitive Decline in PD	Currently available	Immune profiling	CSF Plasma	Healthy Control Parkinson Disease	N/A	Baseline, 48 months	181
54	Shawn Ritchie, PhD	Med-Life Discoveries	Validation of Plasmalogen Augmentation as a Viable Drug Target in PD​	Currently available	Plasmalogen​	Plasma	Healthy Control Parkinson Disease SWEDD (legacy)	Genetic subjects	Baseline	182
55	Sebastian Virreira Winter, PhD	OmicEra​	Targeted & Untargeted MS Based Proteomics of Urine in PD	Currently available	Urine proteomics	Urine	Healthy Control Parkinson Disease Prodromal	GBA & LRRK2 subjects	PD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months	190
56	Deniz Kirik	University of Sydney	An in vivo approach to elucidate the pathobiology of PD-associated genes using human diseased neurons	Expected Q3 2024	Whole genome sequencing on midbrain and cortical neurons and astrocytes	Fibroblasts iPSCs	Healthy Control Parkinson Disease	N/A	N/A	193
57	Alejandro Pezzulo, MD	University of Iowa	Multidisciplinary Analysis of Metabolic Dysregulation in Parkinson's Disease	Expected Q2 2024	Metabolic profiling	Fibroblasts	Healthy Control Parkinson Disease	N/A	N/A	194
58	Christos Proukakis, MD, PhD	University College London	Detection of GBA Mutations by Combination of Illumina & nanopore Sequencing​	Currently available	Long read GBA sequencing	DNA from whole blood	Parkinson Disease Prodromal	GBA subjects	Various	195
59	Eline Appelmans, PhD	FNIH	Targeted Proteomics in AMP PD	Currently available	Targeted proteomics (O-Link Explore 1536, AMP PD)​	CSF Plasma	Healthy Control Parkinson Disease	N/A	Baseline & 3 longitudinal timepoints	196
60	Xiqun Chen, MD, PhD	Mass General Hospital​	From Cancer Associations to Altered Immunity in the Pathogenesis of Parkinson’s Disease	Expected Q2 2024	Inflammation	iPSCs	Healthy Control Parkinson Disease	LRRK2 subjects	N/A	197
61	Erika Holzbaur, PhD	UPenn​	Investigating Mitochondrial Trafficking Deficits Across PD Models	Expected Q3 2024	Mitochondrial trafficking​	iPSCs	Healthy Control	Genetic subjects	N/A	198
62	Magdalene Moran, PhD	Caraway Therapeutics​	Developing TMEM175 Activators as Therapeutics for PD	Currently available	TMEM175 activators​	iPSCs	Parkinson Disease	GBA subjects	N/A	199
63	Adam Mamais, PhD	University of Florida​	Converging Pathways of LRRK2 & PINK1 Biology Impacting Iron Homeostasis & Mitochondrial Function	Currently available	Iron & mitochondrial homeostasis​	iPSCs	Healthy Control Parkinson Disease	LRRK2 subjects	N/A	202
64	Massimiliano Bianchi	Ulysses Neuroscience Ltd	Validation of microtubule dynamics as a novel target in Parkinson’s disease	Expected Q2 2024	Microtubule dynamics in midbrain-like 3D organoid cultures	iPSCs	Healthy Control Parkinson Disease Prodromal	iPD, Hyposmic	N/A	203
65	George Tofaris, MD, PhD	University of Oxford	Serum Neuronal Exosomes as Predictive or Dynamic Biomarkers in PD	Partially available	Neuronal exosomes (aSyn)​	Serum	Healthy Control Parkinson Disease Prodromal	GBA, LRRK2, RBD, Hyposmic	Baseline, 3, 6 Months	204
66	Kiroaki Kaku, PhD	Western Michigan University​	The Role of FAIM in Parkinson’s Disease​	Expected Q4 2024	FAIM	iPSCs	Parkinson Disease	GBA & SNCA subjects	N/A	206
67	Karen MacLeod, Claudio Soto, PhD	Amprion	Development and Optimization of Semi-Quantitate PMCA for Analysis of Soluble ASYN Aggregates in CSF in Amprion's Clinical Laboratory	Currently available	aSyn seeding (PMCA)	CSF	Healthy Control Parkinson Disease	N/A	Various	207	Used warmed CSF from various visits
68	Gallen Triana-Baltzer	Janssen	ptau 217 in the Parkinson Progression Marker Initiative (PPMI)	Expected Q3 2025	Tau	Plasma	Parkinson Disease	LRRK2 subjects	Baseline	208
69	Zinnhardt	Roche	Identification of NLRP3 Inflammasome-related biomarkers in PPMI CSF Samples	Currently available	IL1B	CSF	Healthy Control Parkinson Disease	N/A	Baseline, 12, 24 Months	209
70	Anumantha Kanthasamy, PhD	Iowa State University	PPMI a-Syn Skin Seeding Assay	Currently available	aSyn seeding​ (RT-QuIC)- Round Robin	Skin	Healthy Control Parkinson Disease	N/A	Baseline	211
71	Bahareh Ajami, Dario Alessi	Oregon Health & Science University, University of Dundee	Investigating the influence of genetic risk factors of PD on peripheral immune cells to identify potential biomarkers for prediction of conversion of non-manifesting to manifesting carriers.	Partially available	Immune Cell Phenotyping, transcriptomics and proteomics”	PBMCs Plasma	Parkinson Disease	N/A	N/A	213
72	Khalil Ramadi	New York University	Neural Chemical Delivery System for Treatment of Parkinson's Disease	Expected Q3 2024	Dopamine neuronal cell survival, engraftment, and integration	Fibroblasts iPSCs	Healthy Control Parkinson Disease	N/A	N/A	216
73	Julian Peter Sefrin	Abbvie	Evaluation of TMPRSS5 (Spinesin) in the CSF as a potential biomarker for early Parkinson’s disease diagnosis and progression	Currently available	Spinesin	CSF	Parkinson Disease Prodromal	Phenoconverters, Short Duration iPD, Genetic Subjects, Hyposmic, RBD	Baseline, 6, 12, 24, 36, 48, 60 Months	219
74	Omar Mabrouk	Biogen	CSF total LRRK2 measurements as a Biomarker in genetic PD	Partially Available	LRRK2	CSF	Healthy Control Parkinson Disease Prodromal	GBA & LRRK2 subjects	Baseline, 24 Months	221
75	Aparna Vasanthakumar	Abbvie	O-Link in PPMI	Currently Available	Targeted proteomics	CSF Plasma			Baseline, 6, 12, 24, 36, 48, 60 months	222
76	Anthony Schapira	UCL Medical School	The genome-microbiome axis in the cause of Parkinson disease: Mechanistic insights and therapeutic implications from experimental models and a genetically stratified patient population	Expected Q2 2024	Assessing PD phenotypes in enteric neurons, dopaminergic neurons, astrocytes, microglia	iPSCs	Healthy Control Parkinson Disease	N/A	N/A	223
77	Céline Galvagnion	University of Copenhagen	Understanding selective neuronal vulnerability in the context of Parkinson's Disease	Expected Q3 2024	Proteomics and lipidomics in dopamine and cortical neurons	iPSCs	Healthy Control Parkinson Disease	LRRK2, iPD	N/A	224
78	Susanna Narkilahti	University of Tampere	Electrophysiological Phenotype Characterization of iPSC-derived Neuronal Cells with PD-linked LRRK2 Mutations during Network Formation and Alpha-Synuclein Seeded Aggregation	Expected Q1 2025	electrophysiological phenotype	iPSCs	Healthy Control Parkinson Disease Prodromal	LRRK2 G2019S, LRRK2 R1441G	N/A	227
79	Mark Cookson, PhD	NIH	FOUNDIN[mu]- a microglial resource for PPMI lines	Expected Q1 2025	ATACseq and RNAseq in microglia	iPSCs	Healthy Control Parkinson Disease	N/A	N/A	228
80	Sonia Gandhi	University College London	Defining mechanisms in neurons and oligodendrocytes that drive progression in Parkinson’s	Expected Q4 2024	High content imaging, transcriptomics in dopamine neurons and oligodendrocytes	iPSCs	Healthy Control Parkinson Disease Prodromal	iPD, SNCA (A53T), Hyposmic, RBD	N/A	229
81	Rhalena Thomas	McGill University	A pipeline for massive multiplexing of iPSC-derived dopaminergic neurons and microglia for cohort-scale transcriptomics in PD	Expected Q4 2024	scRNAseq profiling of pooled iPSC dervied neurons and microglia	iPSCs	Healthy Control Parkinson Disease Prodromal	iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmic	N/A	230
82	Lezanne Ooi	University of Wollongong	Metabolic phenotyping in PD dopaminergic neurons and neuronal-glial co-cultures using high-throughput single-cell metabolomics and lipidomics	Expected Q2 2024	Single cell metabolomics and lipidomics in dopamine neurons, Astrocytes, Microglia	iPSCs	Healthy Control Parkinson Disease Prodromal	iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmic	N/A	231
83	Gist Croft	The New York Stem Cell Foundation	A cohort-wide resource of transcriptomic and morphological phenotypes in defined neural cell types	Expected Q1 2025	RNAseq and cell painting in NGN2 neurons and cortical excitatory neurons	iPSCs	Healthy Control Parkinson Disease Prodromal	iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmic, RBD	N/A	232
84	Yuriy Pomeshchik	Lund University	Uncovering proteomic alterations in Parkinson’s disease using patient-specific iPSC-derived brain cells	Expected Q2 2024	Proteomics in neurons, astrocytes and oligodendrocytes	iPSCs	Healthy Control Parkinson Disease Prodromal	iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmic	N/A	233
85	Laurent Roybon	VARI	Omic-based analyses of PD iPSC-derived brain cells	Expected Q1 2025	Multi-omics characterization of diverse cell types (DA neurons & cortical neurons, astrocytes, oligodendrocyte, and microglia)	iPSCs	Healthy Control Parkinson Disease Prodromal	iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmic	N/A	234
86	Lalitha Madhavan	University of Arizona	Deep phenotyping of PD relevant mitochondrial and autophagic mechanisms in human iPSC-derived neural cells	Expected Q4 2024	mitochondrial and autophagic phenotypes/alpha-synuclein	iPSCs	Healthy Control Parkinson Disease	iPD, HC	N/A	235
87	Souvik Modi	ESYA Labs	ESYA PD360: A multi-parametric platform for establishing a novel lysosome-based biomarker and identifying therapeutic interventions for Parkinson’s Disease	Expected Q2 2024	RNAseq, pH, calcium and autophagy analyses in fibroblasts	Fibroblasts	Healthy Control Parkinson Disease	iPD	N/A	236
88	Luis Concha, PhD	Amprion	Analysis of CSF samples	Ongoing availability	Alpha-Synuclein Seeds	CSF	Healthy Control Parkinson Disease Prodromal	N/A	Baseline, 6, 12 Months	237
89	Daniel Ysselstein	Vanqua Bio	Glucocerebrosidase Activation as a Therapeutic Strategy for Parkinson’s Disease	Expected Q1 2025	Longitudinal assessment of GCase activity, insoluble aSyn, sphingolipids, and lysosomal dysfunction in DA neurons	iPSCs	Healthy Control Parkinson Disease	GBA, iPD	N/A	239
90	Nick Hertz, PhD	Mitokinin	Assessing pS65 Ubiquitin levels in biofluids as a biomarker for Parkinson's Disease	Currently available	pS65Ub	CSF Plasma	Healthy Control Parkinson Disease Prodromal	N/A	Baseline, 6, 12, 24, 36, 48, 60 months	240
91	Hilde Nilsen	Oslo University Hospital	Mitochondrial Transcription regulation via Base Excision Repair	Expected Q1 2025	NTHL1	iPSCs	Healthy Control Parkinson Disease Prodromal	SNCA	N/A	241
92	Michael Schwarzchild	Massachusetts General Hospital	Metabolomic Analysis of Penetrance, Prognosis and Tracking Biomarkers of LRRK2 PD	Expected Q2 2024	B12	CSF Plasma	Healthy Control Parkinson Disease Prodromal	GBA & LRRK2 subjects	Plasma: Baseline,12, 24 months; CSF: Baseline only	243
93	Dave Sulzer	Research Foundation for Mental Hygiene, Inc.	Adaptive immunity in the etiology and progression of Parkinson’s disease	Currently available	aSyn-reactive T cells	PBMCs	Healthy Control Parkinson Disease Prodromal			245
94	Ivan Martinez-Valbuena	University of Toronto	Developing a standardized skin-based alpha-synuclein seeding amplification assay for the diagnosis of Parkinson’s disease	Expected Q3 2024	SAA	Tissue	Healthy Control Parkinson Disease	N/A	BL, 6, 48,	248
95	Nobutaka Hattori	Juntendo	Validation of a Serum Synuclein Seed Amplification Assay IP/SAA in PPMI	Expected Q2 2024	SAA	Serum	Parkinson Disease	N/A	Baseline, 6, 12 Months	249
96	Joanne Trinh	Institute of Neurogenetics, Luebeck	Interaction of the environment and somatic modifiers in mitochondrial genes on disease penetrance	Expected Q3 2027	mitochondrial DNA variations	DNA from whole blood	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	N/A	SC and Baseline	250
97	Maximilliano Gutierrez, PhD	The Francis Crick Institute	The impact of the LRRK2 G2019S mutation on lysosomal function in macrophages	Expected Q1 2026	LRRK2 kinase activity	iPSCs	Parkinson Disease	N/A	N/A	254
98	Sarah Huntwork-Rodriguez	Denali	Metabolomic Analysis of Penetrance, Prognosis and Tracking Biomarkers of LRRK2 PD	Expected Q4 2024	Polyanmines	CSF Plasma	Healthy Control Parkinson Disease Prodromal	GBA & LRRK2 subjects	Plasma: Baseline,12, 24 months; CSF: Baseline only	261